Vaxart addresses FAQs about reverse stock split proposal

Vaxart (VXRT) addresses frequently asked stockholder questions regarding a reverse stock split proposal at the Company’s Annual Meeting taking place on Wednesday, May 21, 2025, to regain Nasdaq compliance. The questions said, in part, ” 1) Why is Vaxart proposing a reverse stock split? a. Vaxart is at risk of being delisted from Nasdaq since the Company’s share price is not in compliance with their minimum $1.00 bid price requirement. A reverse split of the Company’s common stock enables Vaxart to regain compliance and helps to ensure that the Company’s common stock can remain listed on Nasdaq. 2) Will the Reverse Stock Split change the value of my investment? a. No. The reverse stock split does not impact the aggregate value of a stockholder’s investment or percentage ownership interest in the Company, except with respect to the treatment of fractional shares. Stockholders will own fewer shares at an anticipated higher price per share. 3) Will the Reverse Stock Split cause dilution in Vaxart’s stock? a. No. The reverse split only causes a change for all issued shares of Vaxart’s common stock uniformly.”